Try our new AI-powered search
beta
In the shade of a tree outside a clinic in Wakiso near Kampala, Uganda’s capital, Hadijah Mirembe watches over her nine-month-old son. She has been here for two days, ever since his temperature soared. He has malaria, she explains, as his chest rises and falls rapidly in his sleep. So does she. These days, even when she sleeps under a net, she often wakes to find a satisfied mosquito that has snuck inside.
Millions of parents in Africa know the worry of caring for a child with malaria. Many know the grief of losing one. But two new vaccines give hope. The first, rts,s/as01, has been tried on nearly 2m children in Kenya, Ghana and Malawi since 2019, and is being used in seven more countries this year. The second, r21/Matrix-m, which is being made in larger volumes at less than half the price, started shipping on May 24th to the Central African Republic.
This article appeared in the Middle East & Africa section of the print edition under the headline “Buzz kill”
Discover stories from this section and more in the list of contents
The country now faces its biggest test since the end of apartheid
The civil war’s outcome may be affected by it
But the main armed forces men may still end up in charge
Published since September 1843 to take part in “a severe contest between intelligence, which presses forward, and an unworthy, timid ignorance obstructing our progress.”
To enhance your experience and ensure our website runs smoothly, we use cookies and similar technologies.
Copyright © The Economist Newspaper Limited 2024. All rights reserved.

More Stories
The Shift in Peering Threatening the Internet’s Foundations
Remembering Alan Barrett: A Builder of the African Internet
From Email to Case Study: What We Learned About Connecting Refugee Communities in Just One Year